来那度胺是浆细胞骨髓瘤自体移植后的标准治疗吗?
本文综述了来那度胺用于浆细胞骨髓瘤患者大剂量治疗及自体造血干细胞移植后维持治疗的证据,采用GRADE方法评价证据质量。作者认为,移植后来那度胺改善无进展生存期的证据质量高,但生存获益的证据质量仅为中等,且新发癌症风险增加的说法存在不一致性,建议基于缓解状态、危险分层和移植后MRD检测结果进行个体化决策。
要点
- 移植后来那度胺改善无进展生存期(PFS)的证据质量高(GRADE)。
- 移植后来那度胺生存获益的证据质量中等,存在不一致性和不精确性。
- 移植后来那度胺是否增加新发癌症风险的说法存在不一致性。
核心结论
- 移植后来那度胺改善PFS的证据质量高,但生存获益的证据质量中等。
- 移植后来那度胺是否增加新发癌症风险的说法存在不一致性。
- 移植后来那度胺的使用应基于移植前和移植后变量(如缓解状态、危险分层和/或移植后MRD检测结果)个体化决定。
- 这些变量在估计移植后来那度胺获益和风险中的有效性应在随机临床试验中检验。
研究设计与样本
- 本文为综述,批判性分析了移植后来那度胺用于浆细胞骨髓瘤的证据,并采用GRADE方法评价证据质量。
主要发现
- 移植后来那度胺改善PFS的证据质量高(GRADE)。
- 移植后来那度胺生存获益的证据质量中等,存在不一致性和不精确性。
- 移植后来那度胺增加新发癌症风险的说法存在不一致性。
关键数值与推荐
- 移植后来那度胺改善PFS的证据质量高(GRADE)。
- 移植后来那度胺生存获益的证据质量中等(GRADE)。
临床怎么用
- 移植后来那度胺的使用应基于移植前和移植后变量(如缓解状态、危险分层和/或移植后MRD检测结果)个体化决定。
- 这些变量在估计移植后来那度胺获益和风险中的有效性应在随机临床试验中检验。
局限性
- 关于生存获益的结论存在不一致性和不精确性。
- 移植后来那度胺增加新发癌症风险的说法存在不一致性。
- 这些变量在估计移植后来那度胺获益和风险中的有效性应在随机临床试验中检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Three randomized controlled trials and a meta-analysis reported lenalidomide given after high-dose therapy and an autologous hemopoietic cell transplantation is associated with increase in progression-free survival (PFS) and survival in persons with plasma cell myeloma (PCM). Based on these data, posttransplant lenalidomide is considered by many a standard-of-care in this setting. However, decisions on the use of new therapies should consider not only results of such trials and meta-analyses but also other factors including quality-of-evidence, anticipated desired and undesired effects of the drug, costs and feasibility of the therapy option. In this review, we critically analyzed evidence on posttransplant lenalidomide in PCM, and we identified criteria which should be considered in designating posttransplant lenalidomide the standard-of-care. Using Grading of Evidence, Assessment, Development and Evaluation (GRADE) approach we judged posttransplant lenalidomide improves PFS with high-quality evidence. However, we identified inconsistency and imprecision as limitations in the conclusions regarding a survival benefit rating the quality-of-evidence for a survival benefit moderate. We also highlighted inconsistency in claims of an increased risk of new cancers associated with posttransplant lenalidomide. We emphasize the need for a value-based reasoning which considers PFS and survival as well as health-related quality-of-life and costs. We conclude the decision to use posttransplant lenalidomide should be individualized based on pre- and posttransplant variables such as remission state, risk category and/or posttransplant measurable residual disease (MRD)-test results. Validity of these variables in estimating benefits and risks of posttransplant lenalidomide should be tested in randomized clinical trials.
引用
- Barosi G, Gale RP. Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma? Leukemia. 2019. PMID: 30692596. doi:10.1038/s41375-019-0383-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。